Abstract
The pharmaceutical industry is developing new collaborative models for drug development. This article discusses the experience so far of the Innovative Medicines Initiative, which is currently the largest public–private partnership that is dedicated to pharmaceutical innovation, highlighting lessons learned for the success of precompetitive consortia.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
“A good collaboration is based on unique contributions from each side”: assessing the dynamics of collaboration in stem cell science
Life Sciences, Society and Policy Open Access 04 May 2017
-
StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium
Stem Cell Reviews and Reports Open Access 30 May 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Abbott, A. The drug deadlock. Nature 468, 158–159 (2010).
Bel, E. H. et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 23 Nov 2010 (doi:10.1136/thx.2010.153643).
Acknowledgements
I would like to thank S. Black, K. De Rijck, A. Juliens and M. Poinot for their valuable assistance in the preparation of the paper, and A. Smith for his critical reading of the manuscript and useful suggestions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Michel Goldman is the Executive Director of the Innovative Medicines Initiative.
Supplementary information
Supplementary information Table S1
Ongoing projects of the Innovative Medicines Initiative in 2011 (PDF 299 kb)
Supplementary information Box S2
Intellectual property in the Innovative Medicines Initiative (PDF 242 kb)
Rights and permissions
About this article
Cite this article
Goldman, M. Reflections on the Innovative Medicines Initiative. Nat Rev Drug Discov 10, 321–322 (2011). https://doi.org/10.1038/nrd3434
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3434
This article is cited by
-
“A good collaboration is based on unique contributions from each side”: assessing the dynamics of collaboration in stem cell science
Life Sciences, Society and Policy (2017)
-
StemBANCC: Governing Access to Material and Data in a Large Stem Cell Research Consortium
Stem Cell Reviews and Reports (2015)
-
The Emergence of Regulatory Science in Pharmaceutical Medicine
Pharmaceutical Medicine (2013)
-
The Innovative Medicines Initiative: A European Response to the Innovation Challenge
Clinical Pharmacology & Therapeutics (2012)
-
Unraveling the autoimmune translational research process layer by layer
Nature Medicine (2012)
